2018 Competitor Analysis: hTERT-Targeted Immunotherapy - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Competitor Analysis: hTERT-Targeted Immunotherapy” report has been added to ResearchAndMarkets.com’s offering.
This Competitive Intelligence report analyzes the competitive field of hTERT-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.
The report includes a compilation of currently active projects in research and development of vaccines, Cytotoxic T-Lymphocytes (CTLs), small molecules and oncolytic viruses targeting human telomerase reverse transcriptase (hTERT). In addition, the report lists company- and institution-specific R&D pipelines of hTERT-Targeted Immunotherapies.
Human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, is one of two essential components of telomerase, an enzyme complex that generates and maintains telomeres. Telomerase is expressed mainly in embryonic and adult stem cells.
Telomere biology has recently been implicated in the pathogenesis of a variety of diseases, and mutations in telomerase components result in a predisposition to solid malignancies. More recent findings show that TERT is not only expressed in late stage primary tumor cells and metastatic cells, but also expressed in incipient cancer stem cells and/or tumor-initiating cells, indicating that TERT has essential roles at every stage of tumorigenesis.
The intracellular protein hTERT is widely overexpressed in human cancers including prostate cancer. Along with its regulation of the telomere, hTERT was also shown to regulate various signal transduction mechanisms involving DNA damage response, cell cycle checkpoint, and apoptosis. The majority of human solid tumors display telomerase activity, which was found to be well correlated with hTERT expression, and hTERT inhibition led to reduced telomerase activity and telomere length.
Competitor projects are listed in a tabular format providing information on:Drug Codes Target/Mechanism of Action Class of Compound Company Product Category Indication R&D Stage Additional comments with a hyperlink leading to the source of information.
Key Topics Covered
1. hTERT-Targeted ImmunotherapyhTERT-Selective Cancer Vaccines hTERT-Specific, Multi-Target Cancer Vaccines hTERT-Targeted Adoptive Cell Therapy Other hTERT-Targeted Immunotherapies
2. Corporate & Institutional hTERT Immunotherapy R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/vc2jlh/2018_competitor?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006267/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: STEM CELLS HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/13/2018 05:47 PM/DISC: 06/13/2018 05:47 PM